AKBA - アケビア・セラピュ―ティクス （Akebia Therapeutics Inc.） アケビア・セラピュ―ティクスAKBAのチャート
AKBAの企業情報
| symbol | AKBA |
|---|---|
| 会社名 | Akebia Therapeutics Inc （アケビア・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アケビ・セェラァピュゥーティィクス（Akebia Therapeutics Inc.）はバイオ医薬品企業である。同社は低酸素誘導性因子（HIF）の生物学に基づいた治療薬の開発と商品化に従事する。同社の主力な候補製品のバダデュスタットは、慢性腎疾患（CKD）における貧血の治療に適応される。同社は経口療法におけるバダダスタットの開発を行う。バダスタットは、CKDの貧血の治療のためのフェーズⅢ開発におけるHIF-プロリルヒドロキシラーゼ（HIF-PH）阻害剤である。また、同社は疾患を標的とするHIFベースの候補製品のポートフォリオの開発に従事する。同社のポートフォリオは、社内で開発された候補製品のAKB-6899、ライセンス取得済みの候補製品のAKB-5169を含む。AKB-5169は、炎症性腸疾患（IBD）のための経口治療として開発中の前臨床化合物である。 アケビア・セラピュ―ティクスは米国のバイオ医薬品会社。低酸素誘導因子、HIF、生物学と腎臓病の患者用製品の商品化に基づく独自の治療法の開発に焦点を当てる。 ｢HIF｣は体内で赤血球の生産と貧血を治療する。｢AKB-6548｣は一日一回の経口療法、｢AKB-6548｣は安定的にヘモグロビンレベルを上昇させる。本社はマサチュ―セッツ州ケンブリッジ。 Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. |
| 本社所在地 | 245 First Street Suite 1100 Cambridge MA 02142 USA |
| 代表者氏名 | Muneer A. Satter ムネア・サッター |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 617-871-2098 |
| 設立年月日 | 39114 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 114人 |
| url | www.akebia.com |
| nasdaq_url | https://www.nasdaq.com/symbol/akba |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -72.19200 |
| 終値（lastsale） | 8.59 |
| 時価総額（marketcap） | 490029976.17 |
| 時価総額 | 時価総額（百万ドル） 484.88320 |
| 売上高 | 売上高（百万ドル） 223.32200 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 82.76020 |
| 当期純利益 | 当期純利益（百万ドル） -68.34100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Akebia Therapeutics Inc revenues increased 92% to $94.7M. Net loss decreased 13% to $57.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-based Compensation in R&D decrease of 72% to $1.4M (expense) Interest income increase from $1M to $2.6M (income) Other Non Rec. |
AKBAのテクニカル分析
AKBAのニュース
Akebia Extends Gains after Piper Sandler’s Positive Take on Vadadustat 2023/05/31 13:47:39 TipRanks
Shares of biopharmaceutical company Akebia Therapeutics (NASDAQ:AKBA) are up 3% at the time of writing today after Piper Sandler analyst Allison Br…
Akebia jumps 16% as Piper upgrades after updates on kidney disease candidate 2023/05/31 12:56:48 Seeking Alpha
Akebia Therapeutics (AKBA) shares rose pre-market Wednesday as Piper Sandler upgraded citing the latest updates on its kidney disease drug, vadadustat. Read more here.
Akebia Therapeutics Soars on Way Forward for Vadadustat in the U.S. 2023/05/30 15:18:57 TipRanks
Biopharmaceutical company Akebia Therapeutics (NASDAQ:AKBA) has received a response for its formal dispute resolution request associated with the c…
Akebia says FDA denied appeal for kidney disease candidate 2023/05/30 12:21:37 Seeking Alpha
Akebia Therapeutics (AKBA) announced Tuesday that the FDA denied its appeal regarding the agency''s decision to reject its kidney disease drug vadadustat. Read more here.
Akebia Therapeutics: Buy This Undervalued Stock At Just 77% Of Revenue 2023/05/29 12:11:16 Seeking Alpha
Akebia Therapeutics'' valuation should be at least $716 million, more than 3x its current valuation. Read more to see why I would rate AKBA stock as Strong Buy.
Akebia Therapeutics Inc. (AKBA) Has A Bright Growth Prospects For 2022 2022/10/31 12:30:00 Marketing Sentinel
Akebia Therapeutics Inc. (NASDAQ:AKBA) has a beta value of 1.39 and has seen 1.21 million shares traded in the last trading session. The company, currently valued at $49.90M, closed the last trade at $0.26 per share which meant it lost -$0.01 on the day or -4.24% during that session. The AKBA stock price is -1188.46% … Akebia Therapeutics Inc. (AKBA) Has A Bright Growth Prospects For 2022 Read More »
Akebia Therapeutics Announces Poster Presentation at ASN Kidney Week 2022 2022/10/21 12:30:00 PR Newswire
CAMBRIDGE, Mass., Oct. 21, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the American Society of Nephrology Kidney Week 2022…
Is the Akebia Therapeutics Inc. (NASDAQ:AKBA) stock an investment opportunity? 2022/10/17 18:30:00 US Post News
Akebia Therapeutics Inc. (AKBA)’s stock has witnessed a price hike of 1.90% from the previous close with its current price standing at $0.29. Its current price is -91.20% under its 52-week high of $3.35 and 5.32% more than its 52-week low of $0.28. Based on the past 30-day period, the stock price is -25.83% below […]
Akebia Therapeutics (AKBA): FDA Approval Failure, Terminated Partnerships 2022/10/07 14:22:56 Seeking Alpha
Akebia Therapeutics faced substantial operating losses in the past few years and is unlikely to turn profitable soon. Click here to see why I maintain a sell rating on AKBA stock.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2022/10/03 20:05:00 Kwhen Finance
REV Stock Moves Amid Revlon Bankruptcy, Short Squeeze Hopes 2022/07/01 16:25:29 InvestorPlace
Source: Casimiro PT / Shutterstock.com Revlon (NYSE: REV ) stock is on the move Friday as the volatility surrounding the meme stock continues following its bankruptcy announcement. Revlon has been a hot name among retailers recently as investors hold out hopes for a short squeeze of the stock. The interest in REV stock started to ramp up last month when the company announced a bankruptcy filing. Fintel even listed REV stock as one of the top companies with short-squeeze potential for this week. It’s not just short squeeze hopes that have REV stock on the move. There’s also been rumors circulating that another company may swoop in and buy the failing fashion product maker . While there’s no official word on that, it’s still been keeping investors excited these last couple of weeks. Of course, there is a reason that REV stock is seeing so much price action today. The stock has been experiencing heavy trading ever since markets opened. As a result, some 20 million shares have changed hands as of this writing.
U.S Stocks Turn Lower; Dow Tumbles Over 100 Points 2022/07/01 16:20:16 Benzinga
U.S. stocks turned lower midway through trading, with the Dow Jones dropping more than 100 points on Friday. The Dow traded down 0.44% to 30,639.41 while the NASDAQ fell 0.59% to 10,936.46. The S&P also fell, dropping, 0.46% to 3,767.81. Also check this: RH, Walgreens And 3 Stocks To Watch Heading Into Thursday Leading and Lagging Sectors Utilities shares rose by 1.4% on Friday. Meanwhile, top gainers in the sector included American Water Works Company, Inc. (NYSE: AWK ), up 3% and Atlantica Sustainable Infrastructure plc (NASDAQ: AY ) up 3%. In trading on Friday, energy shares fell by 1.6%. Top Headline The ISM manufacturing index fell to 53 for June from 56.1 in May. Analysts, however, were expecting a reading of 54.9. Equities Trading UP VerifyMe, Inc. (NASDAQ: VRME ) shares shot up 21% to $2.3807 after the company announced liquidation of the G3 VRM Acquisition SPAC and initiated a new share repurchase program. Shares of Akebia Therapeutics, Inc. (NASDAQ: AKBA ) got a boost, shooting 18% to $0.4181 after the company executed an agreement to terminate its vadadustat Collaboration and License Agreements with Otsuka …
Why Is Akebia Therapeutics (AKBA) Stock Up 14% Today? 2022/07/01 16:02:19 InvestorPlace
Source: Shutterstock Akebia Therapeutics (NASDAQ: AKBA ) stock is taking off on Friday after the kidney treatment company revealed the return of rights for vadadustat . Vadadustat is Akebia Therapeutics’ “investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor.” Today’s news has Otsuka returning the rights for the treatment in the U.S., Europe, China, Russia, Canada, Australia, the Middle East, as well as certain other territories. It’s worth noting that with this return of rights, Otsuka is paying a $55 million fee to Akebia Therapeutics. To go along with that, Otsuka is also transferring the marketing authorization application (MAA) in Europe to the company. 7 Butchered Tech Stocks to Buy and Hold John Butler, CEO of Akebia Therapeutics, said this in a press release. “We continue to believe in the potential of vadadustat as an oral treatment for patients with anemia due to chronic kidney disease, and we are pleased to be regaining the full rights to the product in these important markets.” News of Akebia Therapeutics regaining rights to vadadustat also has AKBA seeing heavy trading today.
Why U.S. Stocks Are Trading Higher, Manufacturing Report And More 2022/07/01 14:05:53 Benzinga
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday. The Dow traded up 0.38% to 30,893.82 while the NASDAQ rose 0.50% to 11,084.33. The S&P also rose, gaining, 0.46% to 3,802.86. Also check this: RH, Walgreens And 3 Stocks To Watch Heading Into Thursday Leading and Lagging Sectors Consumer discretionary shares rose by 1.7% on Friday. Meanwhile, top gainers in the sector included Faraday Future Intelligent Electric Inc. (NASDAQ: FFIE ), up 16% and LightInTheBox Holding Co., Ltd. (NYSE: LITB ) up 10%. In trading on Friday, materials shares fell by 0.4%. Top Headline The ISM manufacturing index fell to 53 for June from 56.1 in May. Analysts, however, were expecting a reading of 54.9. Equities Trading UP VerifyMe, Inc. (NASDAQ: VRME ) shares shot up 33% to $2.61 after the company announced liquidation of the G3 VRM Acquisition SPAC and initiated a new share repurchase program. Shares of Akebia Therapeutics, Inc. (NASDAQ: AKBA ) got a boost, shooting 27% to $0.45 after the company executed an agreement to terminate its vadadustat Collaboration and License Agreements with Otsuka Pharmaceutical.
Akebia Therapeutics And 20 Stocks Moving Premarket 2022/07/01 10:56:18 Benzinga
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX ) rose 83.2% to $0.8250 in pre-market trading after dropping 10% on Thursday. Fast Radius, Inc. (NASDAQ: FSRD ) rose 57.2% to $0.9900 in pre-market trading after jumping over 37% on Thursday. Fast Radius recently appointed Pat McCusker as President, Interim CFO and John Nanry as COO. Akebia Therapeutics, Inc. (NASDAQ: AKBA ) rose 33.1% to $0.4701 in pre-market trading after the company executed an agreement to terminate its vadadustat collaboration and license agreements with Otsuka Pharmaceutical. Shift Technologies, Inc. (NASDAQ: SFT ) rose 27.7% to $0.86 in pre-market trading after declining around 7% on Thursday. ECMOHO Limited (NASDAQ: MOHO ) rose 27.5% to $0.2093 in pre-market trading after dropping over 4% on Thursday. AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) rose 22.8% to $0.30 in pre-market trading. OceanPal Inc. (NASDAQ: OP ) rose 15.5% to $0.55 in pre-market trading. OceanPal recently announced entry into agreement to acquire capesize dry bulk vessel.